Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Next steps with ADI-001

Sattva Neelapu • 5 Jun 2022
ASCO 2022
B-Cell Lymphoma Lymphoma ADI-001 CAR-T

Sattva Neelapu, MD, MD Anderson Cancer Center, Houston, TX, outlines next steps in the use of ADI-001, an anti-CD20 CAR-engineered allogeneic gamma delta (γδ) T cells, in adults with B-cell malignancies. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Sattva Neelapu

2:06
ZUMA-12: axi-cel as first-line therapy in high-risk large B-cell lymphoma
Sattva Neelapu • 5 Jun 2022
3:24
ADI-001: anti-CD20 CAR-engineered allogeneic γδ T cells in adults with B-cell malignancies
Sattva Neelapu • 5 Jun 2022
2:43
Long-term follow-up results of ZUMA-5: axi-cel in patients with R/R indolent NHL
Sattva Neelapu • 12 Dec 2021
2:17
ZUMA-12: axicabtagene ciloleucel as a first-line therapy in patients with high-risk LBCL
Sattva Neelapu • 12 Dec 2021

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals